Investments
27Portfolio Exits
15Partners & Customers
10Service Providers
1
Want to inform investors similar to Takeda Pharmaceutical about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Research containing Takeda Pharmaceutical
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Takeda Pharmaceutical in 6 CB Insights research briefs, most recently on Oct 28, 2022.
Latest Takeda Pharmaceutical News
Jan 27, 2023
S.Korea and Japan compete in gastroesophageal reflux drug market HK Inno.N and Daewoong Pharmaceutical are challenging the Tokyo-based Takeda Pharmaceutical, the global market leader By South Korea is battling Japan again, this time on the global market to treat gastroesophageal reflux disease (GERD). South Korea's pharmaceutical product maker HK Inno.N is expanding the number of licensing offices for its GERD drug K-Cab, and Daewoong Pharmaceutical is doing the same for its Fexuclu medicine to take on the global market leader Taekcab made by Takeda Pharmaceutical of Japan. HK Inno.N on Thursday said it recently signed a contract with Europharma, a Brazilian pharmaceutical corporation, to export K-Cab technology. The former will transfer manufacturing technology and know-how to the latter, and Europharma will oversees product development and sales in Brazil for 10 years. Releasing the value of an export contract for pharmaceutical technology is standard, but not for this deal. Europharma requested that such information remain confidential because doing so will help the company gain a competitive edge against Brazilian market leader Takecab. Through its technology transfer deal in Brazil, HK Inno.N has laid the foundation for supplying K-Cab throughout the Americas. The Brazilian market for peptic ulcer medicine in 2020 was worth 800 billion won ($651 million), sixth in the world and No. 1 in South America. HK Inno.N first launched K-Cab in China and the Philippines and seeks to export the drug to 100 countries by 2028. On the same day, Daewoong Pharmaceutical said it applied for approval of Fexuclu with the Food and Drug Authority of Saudi Arabia, the 11th country where the company has filed such an application under its goal to sell the drug in 20 countries by 2025. In 2021, the peptic ulcer medicine market in Saudi Arabia was worth 410 billion won, ranking 12th worldwide and No. 1 in the Middle East. Write to Ji-Hyun Lee at bluesky@hankyung.com 1 Min read 2 Min read
Takeda Pharmaceutical Investments
27 Investments
Takeda Pharmaceutical has made 27 investments. Their latest investment was in Cardurion Pharmaceuticals as part of their Series B on October 10, 2021.
Takeda Pharmaceutical Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
10/28/2021 | Series B | Cardurion Pharmaceuticals | $300M | No | 6 | |
6/30/2021 | Convertible Note | Carmine Therapeutics | $5M | Yes | 1 | |
4/20/2021 | Series A | Adaptate Biotherapeutics | $18M | Yes | 2 | |
4/1/2021 | Seed VC | |||||
10/6/2020 | Seed VC |
Date | 10/28/2021 | 6/30/2021 | 4/20/2021 | 4/1/2021 | 10/6/2020 |
|---|---|---|---|---|---|
Round | Series B | Convertible Note | Series A | Seed VC | Seed VC |
Company | Cardurion Pharmaceuticals | Carmine Therapeutics | Adaptate Biotherapeutics | ||
Amount | $300M | $5M | $18M | ||
New? | No | Yes | Yes | ||
Co-Investors | |||||
Sources | 6 | 1 | 2 |
Takeda Pharmaceutical Portfolio Exits
15 Portfolio Exits
Takeda Pharmaceutical has 15 portfolio exits. Their latest portfolio exit was HilleVax on April 29, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
4/29/2022 | IPO | HilleVax | Public | 5 | |
1/31/2022 | Divestiture | Takeda Pharmaceutical - Gastrointestinal Line | 1 | ||
7/31/2021 | Spinoff / Spinout | HilleVax | 1 | ||
Date | 4/29/2022 | 1/31/2022 | 7/31/2021 | ||
|---|---|---|---|---|---|
Exit | IPO | Divestiture | Spinoff / Spinout | ||
Companies | HilleVax | Takeda Pharmaceutical - Gastrointestinal Line | HilleVax | ||
Valuation | |||||
Acquirer | Public | ||||
Sources | 5 | 1 | 1 |
Takeda Pharmaceutical Acquisitions
22 Acquisitions
Takeda Pharmaceutical acquired 22 companies. Their latest acquisition was Nimbus Lakshmi on December 13, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
12/13/2022 | Acquired | 1 | ||||
1/10/2022 | Series A | $18M | Acquired | 11 | ||
10/27/2021 | Other | Acquired | 4 | |||
3/9/2021 | Series B | |||||
4/16/2020 |
Date | 12/13/2022 | 1/10/2022 | 10/27/2021 | 3/9/2021 | 4/16/2020 |
|---|---|---|---|---|---|
Investment Stage | Series A | Other | Series B | ||
Companies | |||||
Valuation | |||||
Total Funding | $18M | ||||
Note | Acquired | Acquired | Acquired | ||
Sources | 1 | 11 | 4 |
Takeda Pharmaceutical Partners & Customers
10 Partners and customers
Takeda Pharmaceutical has 10 strategic partners and customers. Takeda Pharmaceutical recently partnered with Discovery Education on November 11, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
11/15/2022 | Partner | United States | Takeda and Discovery Education Partner on New Initiative Focusing on Health Equity CHARLOTTE , N.C. and BOSTON November 16 , 2022 / 3BL Media / - Takeda Center for Health Equity and Patient Affairs , a global biopharmaceutical leader , and Discovery Education , the worldwide edtech leader , today announced a new partnership focused on transformative health equity education . | 2 | |
10/26/2022 | Partner | United States | (Taylor Glascock for KHN). $38,398 for a Single Shot of a Very Old Cancer Drug The development of Lupron Depot as an intramuscular shot that suppressed testosterone for months at a time improved patient compliance and also enabled its maker , Abbott Laboratories , and its Japanese partner , Takeda , to extend their patents on the drug into the 2000s , said Dr. Gerald Weisberg , a former Abbott Laboratories scientist who has been critical of the company 's pricing policies . | 1 | |
10/20/2022 | Licensor | Germany | `` The continued development of TAK-227 in partnership with Zedira and Dr. Falk Pharma has the potential to offer A meaningful benefit to patients with celiac disease who suffer from symptoms and ongoing intestinal injury despite maintaining A gluten-free diet , '' said Chinwe Ukomadu , M.D. , Ph.D. , head , Gastroenterology at Takeda Pharmaceutical Company Limited . | 5 | |
9/29/2022 | Partner | ||||
9/22/2022 | Vendor |
Date | 11/15/2022 | 10/26/2022 | 10/20/2022 | 9/29/2022 | 9/22/2022 |
|---|---|---|---|---|---|
Type | Partner | Partner | Licensor | Partner | Vendor |
Business Partner | |||||
Country | United States | United States | Germany | ||
News Snippet | Takeda and Discovery Education Partner on New Initiative Focusing on Health Equity CHARLOTTE , N.C. and BOSTON November 16 , 2022 / 3BL Media / - Takeda Center for Health Equity and Patient Affairs , a global biopharmaceutical leader , and Discovery Education , the worldwide edtech leader , today announced a new partnership focused on transformative health equity education . | (Taylor Glascock for KHN). $38,398 for a Single Shot of a Very Old Cancer Drug The development of Lupron Depot as an intramuscular shot that suppressed testosterone for months at a time improved patient compliance and also enabled its maker , Abbott Laboratories , and its Japanese partner , Takeda , to extend their patents on the drug into the 2000s , said Dr. Gerald Weisberg , a former Abbott Laboratories scientist who has been critical of the company 's pricing policies . | `` The continued development of TAK-227 in partnership with Zedira and Dr. Falk Pharma has the potential to offer A meaningful benefit to patients with celiac disease who suffer from symptoms and ongoing intestinal injury despite maintaining A gluten-free diet , '' said Chinwe Ukomadu , M.D. , Ph.D. , head , Gastroenterology at Takeda Pharmaceutical Company Limited . | ||
Sources | 2 | 1 | 5 |
Takeda Pharmaceutical Service Providers
1 Service Provider
Takeda Pharmaceutical has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Acq - P2P | Investment Bank | Financial Advisor |
Service Provider | |
|---|---|
Associated Rounds | Acq - P2P |
Provider Type | Investment Bank |
Service Type | Financial Advisor |
Partnership data by VentureSource
Takeda Pharmaceutical Team
38 Team Members
Takeda Pharmaceutical has 38 team members, including current Chief Executive Officer, President, Yasuchika Hasegawa.
Name | Work History | Title | Status |
|---|---|---|---|
Yasuchika Hasegawa | Chief Executive Officer, President | Current | |
Name | Yasuchika Hasegawa | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Executive Officer, President | ||||
Status | Current |
Compare Takeda Pharmaceutical to Competitors
Woebot is an automated conversational agent (chatbot) who helps users monitor their mood and learn about themselves. Drawing from a therapeutic framework known as Cognitive Behavior Therapy, Woebot asks people how they're feeling and what is going on in their lives in the format of brief daily conversations. Woebot is powered by artificial intelligence.
Iona Mind is a mental health app that helps users with anxiety and depression. The company's content is derived from evidence-based protocols and Cognitive Behavioural Therapy (CBT).
XRHealth creates medical & wellness applications using XR technology. For instance, XRHealth delivers an enhanced experience and real-time data analytics, for use in clinics and at home, where users can analyze and quantify performance through a digital experience. It was founded in 2016 and is based in Brookline, Massachusetts.
Amelia Virtual Care offers treatment for behavioral and mental health issues through virtual reality immersion therapy. Its solutions allows professionals to treat all kinds of mental disorders from common phobias to anxiety and depression disorders. It was formerly known as Psious. The company was founded in 2013 and is based in Girona Spain.
Meru Health is an online medical clinic treating depression and burnout. Meru Health's treatment program combines psychological treatment modules, patient data, and a licensed therapist. Meru Health individualizes the program based on patients' personal information and needs. It was founded in 2015 and is based in San Mateo, California.
Learn to Live helps sufferers of mental health problems who have been too uncomfortable to ask for help, have struggled to find available psychologists or therapists, grown tired of traditional self-help or just want to try something new. The company also caters to employers, managed behavioral health organizations, employee assistance programs, and universities seeking to expand their mental health offerings for employees/members/students while simultaneously reducing the cost to deliver these programs.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.